CoverageForm 410-K10-Q8-K13D13G13F

HHLA · Hh&l Acquisition Co. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Income Statement

Line itemFY 2022FY 2021
Revenue--
Cost of Revenue--
Gross Profit--
R&D--
SG&A$4.29M$1.64M
Total Operating Expenses--
D&A--
Operating Income($4.47M)($1.81M)
Interest Expense--
Income Tax--
Net Income$17.69M$1.32M
EPS - Basic--
EPS - Diluted--

Balance Sheet

Line itemFY 2022FY 2021
Cash & Equivalents$21.3K$399.9K
Accounts Receivable--
Inventory--
Accounts Payable$170.9K$176.1K
Current Assets$64.9K$726.2K
Total Assets$420.16M$414.75M
Current Liabilities$5.14M$1.33M
Long-term Debt--
Total Liabilities$12.49M$33.17M
Stockholders' Equity($12.32M)$0
Retained Earnings($12.32M)($32.42M)

Cash Flow

Line itemFY 2022FY 2021
Operating Cash Flow($878.7K)($986.3K)
Investing Cash Flow-($414.00M)
Financing Cash Flow$500.0K$415.38M
CapEx--
Free Cash Flow--

Ratios

MetricFY 2022FY 2021
Profitability
Gross margin--
Operating margin--
EBITDA margin--
Net margin--
Free cash flow margin--
FCF / Net income--
R&D / Revenue--
SG&A / Revenue--
Effective tax rate--
Return on assets4.2%0.3%
Return on equity-143.6%-
Return on invested capital--
Liquidity
Current ratio0.010.55
Quick ratio0.010.55
Cash ratio0.000.30
Leverage
Debt / Equity--
Debt / Assets--
Debt / EBITDA--
Interest coverage--
Equity multiplier-34.10-
Liabilities / Assets0.030.08
Efficiency
Asset turnover--
Inventory turnover--
Days sales outstanding--
Days inventory outstanding--
Days payable outstanding--
Cash conversion cycle--
Valuation
P / E--
P / B--
P / S--
EV / EBITDA--
Growth
Revenue growth (YoY)--
Revenue CAGR (3y)--
Revenue CAGR (5y)--
Gross profit growth (YoY)--
Operating income growth (YoY)-147.7%-
Net income growth (YoY)1239.9%-
EPS growth (YoY)--
EPS CAGR (3y)--
EPS CAGR (5y)--
FCF growth (YoY)--
FCF CAGR (5y)--
Book value growth (YoY)--

Stability scores

Piotroski F-score

FY 2022 · 9-point quality

2/9
Weak
  • Net income positive
  • Operating cash flow positive
  • ROA improved YoY
  • Cash flow > net income
  • -Long-term debt decreased
  • Current ratio improved
  • -No share dilution
  • -Gross margin improved
  • -Asset turnover improved

Peer comparison

Same SIC group: Services-Medical Laboratories

CompanyRevenue (last FY)Net marginROE
NTRA$2.31B-9.0%-12.2%
GH$982.02M-42.4%419.2%
LH$13.95B6.3%10.2%
DGX$11.04B9.0%13.8%
CSTL$344.23M-7.0%-5.1%

Comparing HH&L Acquisition Co. against the 5 most active filers in the same SIC group.